Measuring the Socioeconomic Impact of Cancer: A Systematic Review and Standardized Assessment of Patient-Reported Outcomes (PRO) Instruments
Open Access
- 4 April 2025
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 9 (4) , 519-539
Abstract
Background A number of instruments have been developed to measure the socioeconomic impact (SEI) of cancer. A standardized comparison of the quality and content validity of these instruments is lacking. This study aimed to (1) conduct a standardized assessment of the quality of SEI instruments and (2) assess the content validity of these instruments using the conceptual framework developed by the Organization of European Cancer Institutes (OECI) for SEI analysis. Method We identified articles measuring the SEI of cancer with ad hoc and/or validated instruments from an existing database. These articles were the initial pearls in a systematic review of published articles that applied and validated these instruments using the pearl-growing search strategy in PubMed, Web of Science, and Google Scholar databases. The Evaluating the Measurement of Patient-Reported Outcomes (EMPRO) tool was utilized to provide quantitative assessment and comparison of the quality of identified instruments. To examine content validity, we allocated each instrument’s items against the themes and sub-themes of the established conceptual framework for SEI analysis. Results We identified and investigated 21 validation studies using nine original instruments. The number of articles varied significantly among the identified instruments. The COmprehensive Score for financial Toxicity (COST) instrument was the most frequently used, validated in ten different settings, whereas some newer instruments have not been applied yet. This variation resulted in significant differences in EMPRO overall scores among these instruments. Regarding content validity, we found that not all themes of the OECI framework were covered by the content of the instruments. Conclusion The quality and the application of instruments measuring the SEI of cancer varied significantly. The content of the instruments seems not to cover all related themes of the applied OECI framework in this study. Further studies are warranted to confirm the quality and content validity of the instruments measuring the SEI of cancer.Keywords
This publication has 34 references indexed in Scilit:
- The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatmentCA: A Cancer Journal for Clinicians, 2018
- Financial Hardships Experienced by Cancer Survivors: A Systematic ReviewJNCI: Journal of the National Cancer Institute, 2016
- Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)Cancer, 2016
- A Composite Measure of Personal Financial Burden Among Patients With Stage III Colorectal CancerMedical Care, 2014
- Bidirectional Citation Searching to Completion: An Exploration of Literature Searching MethodsPharmacoEconomics, 2014
- The development of a financial toxicity patient‐reported outcome in cancer: The COST measureCancer, 2014
- Development of EMPRO: A Tool for the Standardized Assessment of Patient-Reported Outcome MeasuresValue in Health, 2008
- Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sourcesBMJ, 2005
- The Psychological Sense of Economic Hardship: Measurement Models, Validity, and Cross‐Ethnic Equivalence for Urban FamiliesAmerican Journal of Community Psychology, 2001
- Family and out-of-pocket costs for women with breast cancer.1994